Dalfopristin is primarily used in combination with quinupristin as a synergistic antibiotic treatment for severe infections caused by Gram-positive bacteria. This combination, known as quinupristin/dalfopristin, is particularly effective against infections that are resistant to other antibiotics, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VRE). It is commonly administered in hospital settings for treating complicated skin and soft tissue infections, as well as bacteremia. The drug works by inhibiting bacterial protein synthesis, making it a valuable option for managing infections where traditional antibiotics have failed. Its use is typically reserved for cases where other treatments are ineffective or contraindicated, ensuring its role as a critical tool in combating resistant bacterial infections.